Smaill J - Search Results

1

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

Chan S, Han K, Qu R, Tong L, Li Y, Zhang Z, Cheng H, Lu X, Patterson A, Smaill J, Ren X, Ding J, Xie H, Ding K. Chan S, et al. Among authors: smaill j. Bioorg Med Chem Lett. 2015 Oct 1;25(19):4277-81. doi: 10.1016/j.bmcl.2015.07.089. Epub 2015 Jul 30. Bioorg Med Chem Lett. 2015. PMID: 26259806

2

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.

Palmer BD, Smaill JB, Boyd M, Boschelli DH, Doherty AM, Hamby JM, Khatana SS, Kramer JB, Kraker AJ, Panek RL, Lu GH, Dahring TK, Winters RT, Showalter HD, Denny WA. Palmer BD, et al. Among authors: smaill jb. J Med Chem. 1998 Dec 31;41(27):5457-65. doi: 10.1021/jm9804681. J Med Chem. 1998. PMID: 9876115

3

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ. Smaill JB, et al. J Med Chem. 1999 May 20;42(10):1803-15. doi: 10.1021/jm9806603. J Med Chem. 1999. PMID: 10346932

4

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA. Smaill JB, et al. J Med Chem. 2000 Apr 6;43(7):1380-97. doi: 10.1021/jm990482t. J Med Chem. 2000. PMID: 10753475

5

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA. Smaill JB, et al. J Med Chem. 2001 Feb 1;44(3):429-40. doi: 10.1021/jm000372i. J Med Chem. 2001. PMID: 11462982

6

Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

Palmer BD, Smaill JB, Rewcastle GW, Dobrusin EM, Kraker A, Moore CW, Steinkampf RW, Denny WA. Palmer BD, et al. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1931-5. doi: 10.1016/j.bmcl.2005.01.079. Bioorg Med Chem Lett. 2005. PMID: 15780636

7

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD. Klutchko SR, et al. Among authors: smaill jb. J Med Chem. 2006 Feb 23;49(4):1475-85. doi: 10.1021/jm050936o. J Med Chem. 2006. PMID: 16480284

8

4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.

Palmer BD, Thompson AM, Booth RJ, Dobrusin EM, Kraker AJ, Lee HH, Lunney EA, Mitchell LH, Ortwine DF, Smaill JB, Swan LM, Denny WA. Palmer BD, et al. Among authors: smaill jb. J Med Chem. 2006 Aug 10;49(16):4896-911. doi: 10.1021/jm0512591. J Med Chem. 2006. PMID: 16884302

9

Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.

Smaill JB, Baker EN, Booth RJ, Bridges AJ, Dickson JM, Dobrusin EM, Ivanovic I, Kraker AJ, Lee HH, Lunney EA, Ortwine DF, Palmer BD, Quin J 3rd, Squire CJ, Thompson AM, Denny WA. Smaill JB, et al. Eur J Med Chem. 2008 Jun;43(6):1276-96. doi: 10.1016/j.ejmech.2007.07.016. Epub 2007 Aug 6. Eur J Med Chem. 2008. PMID: 17869387

10

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. Singleton DC, et al. Among authors: smaill jb. Cancer Gene Ther. 2007 Dec;14(12):953-67. doi: 10.1038/sj.cgt.7701088. Epub 2007 Nov 2. Cancer Gene Ther. 2007. PMID: 17975564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters